An engineered bifunctional recombinant molecule that regulates humoral and cellular effector functions of the immune system

Transplantation

Volumn 75, Issue 4, 2003, Pages 542-549

  Pizzolato, Maryellen C ^a   Fodor, William L ^a,b  

^a ALEXION PHARMACEUTICALS   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT; ANIMAL CELL; ANTIBODY DETECTION; ANTIGEN PRESENTING CELL; AORTA; ARTICLE; CELL FUNCTION; CELL SURFACE; CELL SURVIVAL; CELL TRANSPLANTATION; CELLULAR IMMUNITY; CHIMERA; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT INHIBITION; CONFORMATION; CONTROLLED STUDY; CYTOLYSIS; EFFECTOR CELL; ENDOTHELIUM CELL; ENZYME ANALYSIS; EPITOPE MAPPING; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNITY; LEUKEMIA CELL LINE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; SWINE; T LYMPHOCYTE ACTIVATION; XENOGRAFT;

3T3 CELLS; ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD; ANTIGENS, CD59; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; COMPLEMENT SYSTEM PROTEINS; GENETIC COMPLEMENTATION TEST; HUMANS; IMMUNITY, CELLULAR; IMMUNOCONJUGATES; INTERLEUKIN-2; JURKAT CELLS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SWINE; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 0037468394     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000048492.91165.FC     Document Type: Article

References (30)

1. Auchincloss H. Xenogeneic transplantation. Annu Rev Immunol 1998; 16: 433.
2. Hernandez-Fuentes MP, Baker RJ, Lechler RI. The alloresponse. Rev Immunogenet 1999; 1: 282.
3. Turvey SE, Wood KJ. Immunobiology of solid organ transplantation. Int Surg 1999; 84: 279.
4. Kooijmans-Coutinho MF, Hermans J, Schrama E, et al. Interstitial rejection, vascular rejection, and diffuse thrombosis of renal allografts. Predisposing factors, histology, immunohistochemistry, and relation to outcome. Transplantation 1996; 61: 1338.
5. Fedrich R, Toyada M, Czer LS, et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 1999; 67: 385.
6. Candinas D, Belliveau S, Koyamada N, et al. T cell independence of macrophage and natural killer cell infiltration, cytokine production, and endothelial activation during delayed xenograft rejection. Transplantation 1996; 62: 1920.
7. Lin SS, Weidner BC, Byrne GW, et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101: 1745.
8. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338: 1813.
9. Pearson TC, Madsen JC, Larsen CP, et al. Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody Transplantation 1992; 54: 475.
10. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68: 608.
11. Chavin KD, Lau HT, Bromberg JS. Prolongation of allograft and xenograft survival in mice by anti-CD2 monoclonal antibodies. Transplantation 1992; 54: 286.
12. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4Ig. Science 1992; 257: 789.
13. Pearson TC, Alexander DZ, Winn KJ, et al. Transplantation tolerance induced by CTLA-4Ig. Transplantation 1994 57: 1701-1706.
14. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
15. Sun, H, Subbotin V, Chen C, et al. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA-4Ig and anti-CD40 ligand monoclonal antibody. Transplantation 1997; 64: 1838.
16. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1999; 94: 8789.
17. Kennedy SP, Rollins SA, Burton WV, et al. Protection of aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59. Transplantation 1994; 57: 1494.
18. Mullis K, Faloona F, Scharf S, et al. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol 1986; 1: 263.
19. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587.
20. Evans MJ, Hartman SL, Wolff DW, et al. Rapid expression of an anti-human C5 chimeric Fab utilizing a vector that replicates in COS and 293 cells. J Immunol Methods 1995; 184: 123.
21. Costa C, Zhao L, Burton WV, et al. Expression of the human alpha1, 2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype and confers resistance to human serum-mediated cytolysis. FASEB J 1999; 13: 1762.
22. Murray AG, Khodadoust MM, Pober JS, et al. Porcine aortic endothelial cells activate human T cells: direct presentation of MHC antigens and co-stimulation by ligands for human CD2 and CD28. Immunity 1994; 1: 57.
23. Thompson CB, Lindsten T, Ledbeter JA, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A 1989; 84: 1333.
24. Fodor WL, Rollins SA, Guilmette ER, et al. A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex. J Immunol 1995; 155: 4135.
25. Steurer W, Nickerson PW, Steele SW, et al. Ex vivo coating of islet cell allografts with murine CTLA-4fc promotes graft tolerance. J. Immunol 1995; 155: 1165.
26. Gainer AL, Suarez-Pinzon WL, Min WP, et al. Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation 1998; 66: 194.
27. Sutherland RM, Brady JL, Georgiou, HM, et al. Protective effect of CTLA4Ig secreted by transgenic fetal pancreas allografts. Transplantation 2000; 69: 1806.
28. Chahine AA, Yu M, McKernan MM, et al. Immunomodulation of pancreatic islet allografts in mice with CTLA-4 Ig secreting muscle cells. Transplantation 1995; 59: 1313.
29. Sakagami K, Ohsaki T, Ohnishi T, et al. The effect of anti-interleukin 2 monoclonal antibody treatment on the survival of rat cardiac allograft. J Surg Res 1989; 46: 262.
30. Hong JC, Kahan BD. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation 1999; 68: 701.